WHITEHOUSE STATION, N.J. (AP) - Major cost cuts enabled drugmaker Merck & Co. to offset continuing generic competition cutting sales of former blockbuster medicines. Merck's first-quarter profit rose 7 percent and trounced Wall Street expectations.
WHITEHOUSE STATION, N.J. (AP) — Major cost cuts enabled drugmaker Merck & Co. to offset continuing generic competition cutting sales of former blockbuster medicines. Merck's first-quarter profit rose 7 percent and trounced Wall Street expectations.
The maker of the type 2 diabetes pill Januvia said Tuesday that net income was $1.71 billion, or 57 cents per share, up from $1.59 billion, or 52 cents per share, a year earlier.
Excluding one-time items, net income would have been $2.6 billion, or 88 cents per share. That was 9 cents better than analysts surveyed by FactSet expected. The one-time items, which totaled $896 million or 31 cents per share after taxes, were restructuring and acquisition-related costs.
Revenue totaled $10.26 billion. Analysts expected $10.44 billion.
Pharmaceutical sales dropped 5 percent, to $8.45 billion, as cheaper generic copycat pills hammered several off-patent drugs that once brought in billions of dollars a year. Those include asthma and allergy pill Singulair, allergy spray Nasonex and blood pressure drugs Cozaar and Hyzaar.
Merck's top seller, Type 2 diabetes pills Januvia and Janumet, brought in a combined $1.33 billion, up 3 percent. Sales jumped 10 percent to $604 million for immune disorder drug Remicade, and sales also climbed for HIV drug Isentress and several other products.
Consumer health sales dropped 4 percent to $454 million and sales of veterinary medicines declined 3 percent to $813 million.
Merck, based in Whitehouse Station, N.J., reaffirmed its 2014 forecast for profit of $2.15 to $2.47 per share.
"Investing in the best opportunities for growth while being disciplined in managing our cost enabled us to deliver bottom-line performance," CEO Kenneth Frazier said in a statement. "This is an exciting time as we prepare to commercialize the next wave of innovation coming out of Merck's research labs over the next few years."
Follow Linda A. Johnson at www.twitter.com/LindaJ_onPharma